HanchorBio Announces Commitments Made for Initial Listing on the Innovation Board and Subsequent Implementation Status

1. Date of Event: 07/23/2026

2. Company Name: HanchorBio Inc. (Chinese translation: Hanchor Biotechnology Co., Ltd., a Cayman Islands company)

3. Relationship with Company (please enter '本公司' or 'Subsidiary'):本公司 (Parent Company)

4. Cross-shareholding Ratio: Not applicable

5. Reason for Announcement:

Pursuant to the Taiwan Stock Exchange Corporation's letter No. 1151700907 dated April 7, 2026, this announcement discloses the commitments made by the Company upon its initial application for listing on the Innovation Board, and the implementation status as of the second quarter of 2026.

When applying for initial listing on the Innovation Board, the Company submitted the following commitments as required by the Taiwan Stock Exchange Corporation:

I. Disclose in the 'Special Notes' section of the public offering prospectus:

1. Progress and projected market size of each new drug product line currently under development, R&D progress and key clinical indications for each project, new drug technologies adopted in related products (e.g., PD-1/PD-L1 and CD47/SIRPα), and differentiation from competing peers.

2. Expected development and market launch timeline for new drug products, required funding and sources of funding, and specific plans for achieving profitability.

II. Disclose in the public offering prospectus the decision-making process and terms of the HCB101 product licensing agreement signed with Shanghai Henlius Biotech, Inc. (hereinafter 'Henlius') in 2025, and further commit that any future transactions with Henlius shall be submitted to the Audit Committee for approval prior to board discussion.

III. Disclose in the public offering prospectus the impact of the U.S. 'Biosecure Act' passed in December 2025 on the Company's future development, along with associated geopolitical risks and mitigation measures.

IV. Clearly state on the cover of the public offering prospectus in prominent font:

'The Company is applying for initial listing on the Innovation Board under Article 29, Paragraph 2 of the Listing Rules and is not subject to profitability requirements. The Company's business involves significant risks; investors should exercise particular caution.'

'The Company will continue to appoint a lead securities underwriter during the listing year and the subsequent two fiscal years to assist in compliance with the securities laws and regulations of the Republic of China, the rules of the Taiwan Stock Exchange, public announcements, and the listing agreement. If the appointment with the lead underwriter is terminated during the listing period, the Company shall appoint a replacement securities underwriter within one month of the termination becoming effective.'

6. Countermeasures:

I. The above disclosures have already been included in the 'Special Notes' section of the public offering prospectus prepared for the initial public offering and first listing application on the Innovation Board.

II. The agreement with Henlius has been disclosed in the 'Material Contracts' section of the prospectus. The Company has also issued a commitment letter stating that any future material transaction with Henlius will be submitted to the Audit Committee for approval before being presented to the Board of Directors. During Q2 2026, there were no material transactions between the Company and Henlius.

III. The risks related to the U.S. Biosecure Act and geopolitical factors have been disclosed in the 'Industry, Operations, and Other Major Risks' section of the prospectus.

IV. The required notices have been prominently displayed on the cover of the prospectus. Additionally, the Company has signed a commission agreement with the lead securities underwriter to assist in compliance with the securities regulations of the Republic of China.

7. Other Matters to be Disclosed (if the entity involved is a publicly issued company or above, this material information also qualifies as a matter under Article 7, Paragraph 9, Item 9 of the Enforcement Rules of the Securities and Exchange Act that significantly affects shareholders' rights or securities prices): None